Inflammation and chronic heart failure: From biomarkers to novel anti-inflammatory therapeutic strategies

Medicinal Chemistry

Volumn 10, Issue 7, 2014, Pages 682-689

  Bouras, Georgios ^a   Giannopoulos, Georgios ^b   Hatzis, George ^c   Alexopoulos, Dimitrios ^d   Leventopoulos, George ^e   Deftereos, Spyridon ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Anti TNF therapy; Biomarkers; Chemokines; CRP; Heart failure; Inflammation; Interleukins; TNF

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANDESARTAN; CARVEDILOL; COLCHICINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETANERCEPT; GALECTIN 3; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INFLIXIMAB; LOSARTAN; METALLOPROTEINASE; METHOTREXATE; METOPROLOL; MYELOPEROXIDASE; OLMESARTAN; OMEGA 3 FATTY ACID; OSTEOPROTEGERIN; ROSUVASTATIN; TELMISARTAN; THALIDOMIDE; VALSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FIBROBLAST; FIBROSIS; GENE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTROPHY; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; ANIMAL; CHEMISTRY; CHRONIC DISEASE; COMPLICATION; METABOLISM; SYNTHESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CHRONIC DISEASE; HEART FAILURE; HUMANS; INFLAMMATION;

EID: 84925634323     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406410666140318113325     Document Type: Article

References (304)

1. Bernard, S.; Maurer, M. S. Heart failure with a normal ejection fraction: treatments for a complex syndrome? Curr. Treat. Options Cardiovasc. Med. 2012, 14(4), 305-18.
2. Elster, S. K.; Braunwald, E.; Wood, H. F. A study of C-reactive protein in the serum of patients with congestive heart failure. Am. Heart J. 1956, 51(4), 533-41.
3. Braunwald, E. Biomarkers in heart failure. N. Engl. J. Med. 2008, 358(20), 2148-59.
4. Bozkurt, B.; Mann, D. L.; Deswal, A. Biomarkers of inflammation in heart failure. Heart Fail. Rev. 2010, 15(4), 331-41.
5. Torre-Amione, G.; Kapadia, S.; Lee, J.; Durand, J. B.; Bies, R. D.; Young, J. B.; Mann, D. L. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93(4), 704-11.
6. Torre-Amione, G.; Kapadia, S.; Lee, J.; Bies, R. D.; Lebovitz, R.; Mann, D. L. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92(6), 1487-93.
7. Katz, S. D.; Rao, R.; Berman, J. W.; Schwarz, M.; Demopoulos, L.; Bijou, R.; Le Jemtel, T. H. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994, 90(1), 12-6.
8. Aukrust, P.; Ueland, T.; Lien, E.; Bendtzen, K.; Muller, F.; Andreassen, A. K.; Nordoy, I.; Aass, H.; Espevik, T.; Simonsen, S.; Froland, S. S.; Gullestad, L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1999, 83(3), 376-82.
9. Mann, D. L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 2002, 91(11), 988-98.
10. Seta, Y.; Shan, K.; Bozkurt, B.; Oral, H.; Mann, D. L. Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. 1996, 2(3), 243-9.
11. Von Haehling, S.; Schefold, J. C.; Lainscak, M.; Doehner, W.; Anker, S. D. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail. Clin. 2009, 5(4), 549-60.
12. Hofmann, U.; Frantz, S. How can we cure a heart "in flame"? A translational view on inflammation in heart failure. Basic Res. Cardiol. 2013, 108(4), 356.
13. Huang, Y.; Yan, L.; Rong, S.; Haller, H.; Kirch, T. TNF-alpha induces endothelial dysfunction via PKC-zeta-dependent NADPH oxidase activation. J. Huazhong. Univ. Sci. Technolog. Med. Sci. 2012, 32(5), 642-7.
14. Panas, D.; Khadour, F. H.; Szabo, C.; Schulz, R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am. J. Physiol. 1998, 275(3 Pt 2), H1016-23.
15. Hori, M.; Yamaguchi, O. Is tumor necrosis factor-alpha friend or foe for chronic heart failure? Circ. Res. 2013, 113(5), 492-4.
16. Moe, G. W.; Marin-Garcia, J.; Konig, A.; Goldenthal, M.; Lu, X.; Feng, Q. In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 2004, 287(4), H1813-20.
17. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H. M.; Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990, 323(4), 236-41.
18. Deswal, A.; Petersen, N. J.; Feldman, A. M.; Young, J. B.; White, B. G.; Mann, D. L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103(16), 2055-9.
19. Torre-Amione, G.; Kapadia, S.; Benedict, C.; Oral, H.; Young, J. B.; Mann, D. L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 1996, 27(5), 1201-6.
20. Zeng, J. R.; Xu, X. L.; Yu, X. J.; Hou, J.; Xu, T. J.; Mi, M.; Li, D. L.; Zang, W. J. [Dynamic correlation of TNF-alpha and IL-10 with myocardial remodeling induced by pressure overload in rats]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012, 28(7), 699-701, 08.
21. Flesch, M.; Hoper, A.; Dell'Italia, L.; Evans, K.; Bond, R.; Peshock, R.; Diwan, A.; Brinsa, T. A.; Wei, C. C.; Sivasubramanian, N.; Spinale, F. G.; Mann, D. L. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2003, 108(5), 598-604.
22. Vasan, R. S.; Sullivan, L. M.; Roubenoff, R.; Dinarello, C. A.; Harris, T.; Benjamin, E. J.; Sawyer, D. B.; Levy, D.; Wilson, P. W.; D'Agostino, R. B. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107(11), 1486-91.
23. Maeda, K.; Tsutamoto, T.; Wada, A.; Mabuchi, N.; Hayashi, M.; Tsutsui, T.; Ohnishi, M.; Sawaki, M.; Fujii, M.; Matsumoto, T.; Kinoshita, M. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol. 2000, 36(5), 1587-93.
24. Le Maitre, J. P.; Harris, S.; Fox, K. A.; Denvir, M. Change in circulating cytokines after 2 forms of exercise training in chronic stable heart failure. Am. Heart J. 2004, 147(1), 100-5.
25. Rauchhaus, M.; Doehner, W.; Francis, D. P.; Davos, C.; Kemp, M.; Liebenthal, C.; Niebauer, J.; Hooper, J.; Volk, H. D.; Coats, A. J.; Anker, S. D. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102(25), 3060-7.
26. Chin, B. S.; Blann, A. D.; Gibbs, C. R.; Chung, N. A.; Conway, D. G.; Lip, G. Y. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur. J. Clin. Invest. 2003, 33(11), 941-8.
27. Ng, S. B.; Tan, Y. H.; Guy, G. R. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J. Biol. Chem. 1994, 269(29), 19021-7.
28. Sanceau, J.; Kaisho, T.; Hirano, T.; Wietzerbin, J. Triggering of the human interleukin-6 gene by interferon-gamma and tumor necrosis factor-alpha in monocytic cells involves cooperation between interferon regulatory factor-1, NF kappa B, and Sp1 transcription factors. J. Biol. Chem. 1995, 270(46), 27920-31.
29. Von Haehling, S.; Lainscak, M.; Springer, J.; Anker, S. D. Cardiac cachexia: a systematic overview. Pharmacol. Ther. 2009, 121(3), 227-52.
30. Van Kimmenade, R. R.; Januzzi, J. L. Jr. Emerging biomarkers in heart failure. Clin. Chem. 2012, 58(1), 127-38.
31. Baumann, H.; Gauldie, J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol. Biol. Med. 1990, 7(2), 147-59.
32. Munger, M. A.; Johnson, B.; Amber, I. J.; Callahan, K. S.; Gilbert, E. M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1996, 77(9), 723-7.
33. Tsutamoto, T.; Hisanaga, T.; Wada, A.; Maeda, K.; Ohnishi, M.; Fukai, D.; Mabuchi, N.; Sawaki, M.; Kinoshita, M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 1998, 31(2), 391-8.
34. Aronson, D.; Mittleman, M. A.; Burger, A. J. Interleukin-6 levels are inversely correlated with heart rate variability in patients with decompensated heart failure. J. Cardiovasc. Electrophysiol. 2001, 12(3), 294-300.
35. Jug, B.; Salobir, B. G.; Vene, N.; Sebestjen, M.; Sabovic, M.; Keber, I. Interleukin-6 is a stronger prognostic predictor than highsensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels 2009, 24(4), 271-6.
36. Jougasaki, M.; Leskinen, H.; Larsen, A. M.; Luchner, A.; Cataliotti, A.; Tachibana, I.; Burnett, J. C. Jr. Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure. Peptides 2003, 24(6), 889-92.
37. Matsushita, K.; Iwanaga, S.; Oda, T.; Kimura, K.; Shimada, M.; Sano, M.; Umezawa, A.; Hata, J.; Ogawa, S. Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab. Invest. 2005, 85(10), 1210-23.
38. Fischer, P.; Hilfiker-Kleiner, D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res. Cardiol. 2007, 102(5), 393-411.
39. Hirota, H.; Izumi, M.; Hamaguchi, T.; Sugiyama, S.; Murakami, E.; Kunisada, K.; Fujio, Y.; Oshima, Y.; Nakaoka, Y.; Yamauchi-Takihara, K. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 2004, 19(5), 237-41.
40. Askevold, E. T.; Nymo, S.; Ueland, T.; Gravning, J.; Wergeland, R.; Kjekshus, J.; Yndestad, A.; Cleland, J. G.; McMurray, J. J.; Aukrust, P.; Gullestad, L. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ. Heart Fail. 2013, 6(1), 91-8.
41. Seta, Y.; Kanda, T.; Tanaka, T.; Arai, M.; Sekiguchi, K.; Yokoyama, T.; Kurimoto, M.; Tamura, J.; Kurabayashi, M. Interleukin-18 in patients with congestive heart failure: induction of atrial natriuretic peptide gene expression. Res. Commun. Mol. Pathol. Pharmacol. 2000, 108(1-2), 87-95.
42. Loppnow, H.; Werdan, K.; Werner, C. The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist. Auton. Autacoid Pharmacol. 2002, 22(2), 83-92.
43. Long, C. S. The role of interleukin-1 in the failing heart. Heart Fail. Rev. 2001, 6(2), 81-94.
44. Van Tassell, B. W.; Arena, R. A.; Toldo, S.; Mezzaroma, E.; Azam, T.; Seropian, I. M.; Shah, K.; Canada, J.; Voelkel, N. F.; Dinarello, C. A.; Abbate, A. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One 2012, 7(3), e33438.
45. Bujak, M.; Frangogiannis, N. G. The role of IL-1 in the pathogenesis of heart disease. Arch. Immunol. Ther. Exp. (Warsz.) 2009, 57(3), 165-76.
46. Tamaki, S.; Mano, T.; Sakata, Y.; Ohtani, T.; Takeda, Y.; Kamimura, D.; Omori, Y.; Tsukamoto, Y.; Ikeya, Y.; Kawai, M.; Kumanogoh, A.; Hagihara, K.; Ishii, R.; Higashimori, M.; Kaneko, M.; Hasuwa, H.; Miwa, T.; Yamamoto, K.; Komuro, I. Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction. PLoS One 2013, 8(7), e68893.
47. Liu, S. J.; Zhou, W.; Kennedy, R. H. Suppression of betaadrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes. Am. J. Physiol. 1999, 276(1 Pt 2), H141-8.
48. Weinberg, E. O.; Shimpo, M.; Hurwitz, S.; Tominaga, S.; Rouleau, J. L.; Lee, R. T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107(5), 721-6.
49. Sanada, S.; Hakuno, D.; Higgins, L. J.; Schreiter, E. R.; McKenzie, A. N.; Lee, R. T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 2007, 117(6), 1538-49.
50. Wojtczak-Soska, K.; Pietrucha, T.; Sakowicz, A.; Lelonek, M. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Arch. Med. Sci. 2013, 9(1), 21-6.
51. Bolger, A. P.; Sharma, R.; Von Haehling, S.; Doehner, W.; Oliver, B.; Rauchhaus, M.; Coats, A. J.; Adcock, I. M.; Anker, S. D. Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. Am. J. Cardiol. 2002, 90(4), 384-9.
52. Lang, R.; Rutschman, R. L.; Greaves, D. R.; Murray, P. J. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J. Immunol. 2002, 168(7), 3402-11.
53. Bogdan, C.; Vodovotz, Y.; Nathan, C. Macrophage deactivation by interleukin 10. J. Exp. Med. 1991, 174(6), 1549-55.
54. Adamopoulos, S.; Parissis, J. T.; Paraskevaidis, I.; Karatzas, D.; Livanis, E.; Georgiadis, M.; Karavolias, G.; Mitropoulos, D.; Degiannis, D.; Kremastinos, D. T. Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur. Heart J. 2003, 24(24), 2186-96.
55. El Azab, S. R.; Rosseel, P. M.; De Lange, J. J.; Groeneveld, A. B.; Van Strik, R.; Van Wijk, E. M.; Scheffer, G. J. Dexamethasone decreases the pro- to anti-inflammatory cytokine ratio during cardiac surgery. Br. J. Anaesth. 2002, 88(4), 496-501.
56. Kaur, K.; Sharma, A. K.; Singal, P. K. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2006, 291(1), H106-13.
57. Amir, O.; Rogowski, O.; David, M.; Lahat, N.; Wolff, R.; Lewis, B. S. Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr. Med. Assoc. J. 2010, 12(3), 158-62.
58. Akira, S. The role of IL-18 in innate immunity. Curr. Opin. Immunol. 2000, 12(1), 59-63.
59. Woldbaek, P. R.; Tonnessen, T.; Henriksen, U. L.; Florholmen, G.; Lunde, P. K.; Lyberg, T.; Christensen, G. Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc. Res. 2003, 59(1), 122-31.
60. Chandrasekar, B.; Mummidi, S.; Claycomb, W. C.; Mestril, R.; Nemer, M. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositidedependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J. Biol. Chem. 2005, 280(6), 4553-67.
61. Netea, M. G.; Kullberg, B. J.; Verschueren, I.; Van Der Meer, J. W. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Eur. J. Immunol. 2000, 30(10), 3057-60.
62. Leung, B. P.; Culshaw, S.; Gracie, J. A.; Hunter, D.; Canetti, C. A.; Campbell, C.; Cunha, F.; Liew, F. Y.; McInnes, I. B. A role for IL-18 in neutrophil activation. J. Immunol. 2001, 167(5), 2879-86.
63. Dao, T.; Ohashi, K.; Kayano, T.; Kurimoto, M.; Okamura, H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell. Immunol. 1996, 173(2), 230-5.
64. Morel, J. C.; Park, C. C.; Woods, J. M.; Koch, A. E. A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J. Biol. Chem. 2001, 276(40), 37069-75.
65. Morel, J. C.; Park, C. C.; Zhu, K.; Kumar, P.; Ruth, J. H.; Koch, A. E. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J. Biol. Chem. 2002, 277(38), 34679-91.
66. Reddy, V. S.; Harskamp, R. E.; Van Ginkel, M. W.; Calhoon, J.; Baisden, C. E.; Kim, I. S.; Valente, A. J.; Chandrasekar, B. Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. J. Cell. Physiol. 2008, 215(3), 697-707.
67. Yu, Q.; Vazquez, R.; Khojeini, E. V.; Patel, C.; Venkataramani, R.; Larson, D. F. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 297(1), H76-85.
68. Nakagomi, A.; Seino, Y.; Endoh, Y.; Kusama, Y.; Atarashi, H.; Mizuno, K. Upregulation of monocyte proinflammatory cytokine production by C-reactive protein is significantly related to ongoing myocardial damage and future cardiac events in patients with chronic heart failure. J. Card. Fail. 2010, 16(7), 562-71.
69. Ballou, S. P.; Lozanski, G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992, 4(5), 361-8.
70. Speidl, W. S.; Exner, M.; Amighi, J.; Kastl, S. P.; Zorn, G.; Maurer, G.; Wagner, O.; Huber, K.; Minar, E.; Wojta, J.; Schillinger, M. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur. Heart J. 2005, 26(21), 2294-9.
71. Torzewski, J.; Torzewski, M.; Bowyer, D. E.; Frohlich, M.; Koenig, W.; Waltenberger, J.; Fitzsimmons, C.; Hombach, V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol. 1998, 18(9), 1386-92.
72. Pepys, M. B.; Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111(12), 1805-12.
73. Volanakis, J. E.; Kaplan, M. H. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J. Immunol. 1974, 113(1), 9-17.
74. Szalai, A. J.; Van Ginkel, F. W.; Wang, Y.; McGhee, J. R.; Volanakis, J. E. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J. Immunol. 2000, 165(2), 1030-5.
75. Giannakis, E.; Male, D. A.; Ormsby, R. J.; Mold, C.; Jokiranta, T. S.; Ranganathan, S.; Gordon, D. L. Multiple ligand binding sites on domain seven of human complement factor H. Int. Immunopharmacol. 2001, 1(3), 433-43.
76. Verma, S.; Li, S. H.; Badiwala, M. V.; Weisel, R. D.; Fedak, P. W.; Li, R. K.; Dhillon, B.; Mickle, D. A. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002, 105(16), 1890-6.
77. Pasceri, V.; Wu, H. D.; Willerson, J. T.; Yeh, E. T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101(3), 235-8.
78. Devaraj, S.; O'Keefe, G.; Jialal, I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J. Clin. Endocrinol. Metab. 2005, 90(8), 4549-54.
79. Paffen, E.; Vos, H. L.; Bertina, R. M. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler. Thromb. Vasc. Biol. 2004, 24(5), 975-81.
80. Pasceri, V.; Cheng, J. S.; Willerson, J. T.; Yeh, E. T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103(21), 2531-4.
81. Devaraj, S.; Kumaresan, P. R.; Jialal, I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J. Mol. Cell. Cardiol. 2004, 36(3), 405-10.
82. Venugopal, S. K.; Devaraj, S.; Yuhanna, I.; Shaul, P.; Jialal, I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106(12), 1439-41.
83. Clapp, B. R.; Hirschfield, G. M.; Storry, C.; Gallimore, J. R.; Stidwill, R. P.; Singer, M.; Deanfield, J. E.; MacAllister, R. J.; Pepys, M. B.; Vallance, P.; Hingorani, A. D. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005, 111(12), 1530-6.
84. Venugopal, S. K.; Devaraj, S.; Jialal, I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003, 108(14), 1676-8.
85. Macdonald, P.; Schyvens, C.; Winlaw, D. The role of nitric oxide in heart failure. Potential for pharmacological intervention. Drugs Aging 1996, 8(6), 452-8.
86. Kardys, I.; Knetsch, A. M.; Bleumink, G. S.; Deckers, J. W.; Hofman, A.; Stricker, B. H.; Witteman, J. C. C-reactive protein and risk of heart failure. The Rotterdam Study. Am. Heart J. 2006, 152(3), 514-20.
87. Pietila, K. O.; Harmoinen, A. P.; Jokiniitty, J.; Pasternack, A. I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur. Heart J. 1996, 17(9), 1345-9.
88. Suleiman, M.; Aronson, D.; Reisner, S. A.; Kapeliovich, M. R.; Markiewicz, W.; Levy, Y.; Hammerman, H. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am. J. Med. 2003, 115(9), 695-701.
89. Suleiman, M.; Khatib, R.; Agmon, Y.; Mahamid, R.; Boulos, M.; Kapeliovich, M.; Levy, Y.; Beyar, R.; Markiewicz, W.; Hammerman, H.; Aronson, D. Early inflammation and risk of longterm development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J. Am. Coll. Cardiol. 2006, 47(5), 962-8.
90. Scirica, B. M.; Morrow, D. A.; Cannon, C. P.; De Lemos, J. A.; Murphy, S.; Sabatine, M. S.; Wiviott, S. D.; Rifai, N.; McCabe, C. H.; Braunwald, E. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin. Chem. 2007, 53(10), 1800-7.
91. Sabatine, M. S.; Morrow, D. A.; De Lemos, J. A.; Gibson, C. M.; Murphy, S. A.; Rifai, N.; McCabe, C.; Antman, E. M.; Cannon, C. P.; Braunwald, E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105(15), 1760-3.
92. Bursi, F.; Weston, S. A.; Killian, J. M.; Gabriel, S. E.; Jacobsen, S. J.; Roger, V. L. C-reactive protein and heart failure after myocardial infarction in the community. Am. J. Med. 2007, 120(7), 616-22.
93. Kavsak, P. A.; MacRae, A. R.; Newman, A. M.; Lustig, V.; Palomaki, G. E.; Ko, D. T.; Tu, J. V.; Jaffe, A. S. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin. Biochem. 2007, 40(5-6), 326-9.
94. Hartford, M.; Wiklund, O.; Mattsson Hulten, L.; Persson, A.; Karlsson, T.; Herlitz, J.; Caidahl, K. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J. Intern. Med. 2007, 262(5), 526-36.
95. Sabatine, M. S.; Morrow, D. A.; Jablonski, K. A.; Rice, M. M.; Warnica, J. W.; Domanski, M. J.; Hsia, J.; Gersh, B. J.; Rifai, N.; Ridker, P. M.; Pfeffer, M. A.; Braunwald, E. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115(12), 1528-36.
96. Williams, E. S.; Shah, S. J.; Ali, S.; Na, B. Y.; Schiller, N. B.; Whooley, M. A. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur. J. Heart Fail. 2008, 10(1), 63-9.
97. Campbell, D. J.; Woodward, M.; Chalmers, J. P.; Colman, S. A.; Jenkins, A. J.; Kemp, B. E.; Neal, B. C.; Patel, A.; MacMahon, S. W. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 2005, 45(1), 69-74.
98. Yin, W. H.; Chen, J. W.; Jen, H. L.; Chiang, M. C.; Huang, W. P.; Feng, A. N.; Young, M. S.; Lin, S. J. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am. Heart J. 2004, 147(5), 931-8.
99. Xue, C.; Feng, Y.; Wo, J.; Li, Y. Prognostic value of highsensitivity C-reactive protein in patients with chronic heart failure. N. Z. Med. J. 2006, 119(1245), U2314.
100. Windram, J. D.; Loh, P. H.; Rigby, A. S.; Hanning, I.; Clark, A. L.; Cleland, J. G. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am. Heart J. 2007, 153(6), 1048-55.
101. Yin, W. H.; Chen, J. W.; Feng, A. N.; Lin, S. J.; Young, S. Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin. Cardiol. 2007, 30(8), 397-402.
102. Tang, W. H.; Shrestha, K.; Van Lente, F.; Troughton, R. W.; Martin, M. G.; Borowski, A. G.; Jasper, S.; Klein, A. L. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am. J. Cardiol. 2008, 101(3), 370-3.
103. Anand, I. S.; Latini, R.; Florea, V. G.; Kuskowski, M. A.; Rector, T.; Masson, S.; Signorini, S.; Mocarelli, P.; Hester, A.; Glazer, R.; Cohn, J. N. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005, 112(10), 1428-34.
104. Lamblin, N.; Mouquet, F.; Hennache, B.; Dagorn, J.; Susen, S.; Bauters, C.; De Groote, P. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur. Heart J. 2005, 26(21), 2245-50.
105. Chirinos, J. A.; Zambrano, J. P.; Chakko, S.; Schob, A.; Veerani, A.; Perez, G. O.; Mendez, A. J. Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am. J. Cardiol. 2005, 95(1), 88-90.
106. Kaneko, K.; Kanda, T.; Yamauchi, Y.; Hasegawa, A.; Iwasaki, T.; Arai, M.; Suzuki, T.; Kobayashi, I.; Nagai, R. C-Reactive protein in dilated cardiomyopathy. Cardiology 1999, 91(4), 215-9.
107. Ronnow, B. S.; Reyna, S. P.; Muhlestein, J. B.; Horne, B. D.; Allen Maycock, C. A.; Bair, T. L.; Carlquist, J. F.; Kfoury, A. G.; Anderson, J. L.; Renlund, D. G. C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. Cardiology 2005, 104(4), 196-201.
108. Lamparter, S.; Grimm, W. Predictive value of high-sensitivity C-reactive protein in patients with idiopathic dilated cardiomyopathy. Pacing Clin. Electrophysiol. 2005, 28(Suppl 1), S233-6.
109. Ishikawa, C.; Tsutamoto, T.; Fujii, M.; Sakai, H.; Tanaka, T.; Horie, M. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ. J. 2006, 70(7), 857-63.
110. Woloshin, S.; Schwartz, L. M. Distribution of C-reactive protein values in the United States. N. Engl. J. Med. 2005, 352(15), 1611-3.
111. Bower, J. K.; Lazo, M.; Juraschek, S. P.; Selvin, E. Within-person variability in high-sensitivity C-reactive protein. Arch. Intern. Med. 2012, 172(19), 1519-21.
112. De Goma, E. M.; French, B.; Dunbar, R. L.; Allison, M. A.; Mohler, E. R. 3rd; Budoff, M. J. Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2012, 224(1), 274-9.
113. Anatoliotakis, N.; Deftereos, S.; Bouras, G.; Giannopoulos, G.; Tsounis, D.; Angelidis, C.; Kaoukis, A.; Stefanadis, C. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Curr. Top. Med. Chem. 2013, 13(2), 115-38.
114. Anker, S. D.; Von Haehling, S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90(4), 464-70.
115. Eleuteri, E.; Di Stefano, A.; Ricciardolo, F. L.; Magno, F.; Gnemmi, I.; Colombo, M.; Anzalone, R.; Cappello, F.; La Rocca, G.; Tarro Genta, F.; Zummo, G.; Giannuzzi, P. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int. J. Cardiol. 2009, 135(3), 386-90.
116. Tang, W. H.; Brennan, M. L.; Philip, K.; Tong, W.; Mann, S.; Van Lente, F.; Hazen, S. L. Plasma myeloperoxidase levels in patients with chronic heart failure. Am. J. Cardiol. 2006, 98(6), 796-9.
117. Askari, A. T.; Brennan, M. L.; Zhou, X.; Drinko, J.; Morehead, A.; Thomas, J. D.; Topol, E. J.; Hazen, S. L.; Penn, M. S. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J. Exp. Med. 2003, 197(5), 615-24.
118. Cameron, V. A.; Mocatta, T. J.; Pilbrow, A. P.; Frampton, C. M.; Troughton, R. W.; Richards, A. M.; Winterbourn, C. C. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 2006, 47(6), 1155-61.
119. Reichlin, T.; Socrates, T.; Egli, P.; Potocki, M.; Breidthardt, T.; Arenja, N.; Meissner, J.; Noveanu, M.; Reiter, M.; Twerenbold, R.; Schaub, N.; Buser, A.; Mueller, C. Use of myeloperoxidase for risk stratification in acute heart failure. Clin. Chem. 2010, 56(6), 944-51.
120. Michowitz, Y.; Kisil, S.; Guzner-Gur, H.; Rubinstein, A.; Wexler, D.; Sheps, D.; Keren, G.; George, J. Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr. Med. Assoc. J. 2008, 10(12), 884-8.
121. Tang, W. H.; Katz, R.; Brennan, M. L.; Aviles, R. J.; Tracy, R. P.; Psaty, B. M.; Hazen, S. L. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am. J. Cardiol. 2009, 103(9), 1269-74.
122. Ng, L. L.; Pathik, B.; Loke, I. W.; Squire, I. B.; Davies, J. E. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am. Heart J. 2006, 152(1), 94-101.
123. Rudolph, V.; Rudolph, T. K.; Hennings, J. C.; Blankenberg, S.; Schnabel, R.; Steven, D.; Haddad, M.; Knittel, K.; Wende, S.; Wenzel, J.; Munzel, T.; Heitzer, T.; Meinertz, T.; Hubner, C.; Baldus, S. Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radic. Biol. Med. 2007, 43(8), 1189-96.
124. Tang, W. H.; Tong, W.; Troughton, R. W.; Martin, M. G.; Shrestha, K.; Borowski, A.; Jasper, S.; Hazen, S. L.; Klein, A. L. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J. Am. Coll. Cardiol. 2007, 49(24), 2364-70.
125. Butler, G. S.; Overall, C. M. Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 2009, 48(46), 10830-45.
126. Rodriguez, D.; Morrison, C. J.; Overall, C. M. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta 2010, 1803(1), 39-54.
127. Maurer, P.; Gohring, W.; Sasaki, T.; Mann, K.; Timpl, R.; Nischt, R. Recombinant and tissue-derived mouse BM-40 bind to several collagen types and have increased affinities after proteolytic activation. Cell. Mol. Life Sci. 1997, 53(5), 478-84.
128. Symoens, S.; Renard, M.; Bonod-Bidaud, C.; Syx, D.; Vaganay, E.; Malfait, F.; Ricard-Blum, S.; Kessler, E.; Van Laer, L.; Coucke, P.; Ruggiero, F.; De Paepe, A. Identification of binding partners interacting with the alpha1-N-propeptide of type V collagen. Biochem. J. 2011, 433(2), 371-81.
129. Dobaczewski, M.; Gonzalez-Quesada, C.; Frangogiannis, N. G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J. Mol. Cell. Cardiol. 2010, 48(3), 504-11.
130. Frangogiannis, N. G. Monomeric C-reactive protein and inflammatory injury in myocardial infarction. Cardiovasc. Res. 2012, 96(1), 4-6.
131. Widgerow, A. D. Cellular/extracellular matrix cross-talk in scar evolution and control. Wound Repair Regen. 2011, 19(2), 117-33.
132. Nistico, P.; Bissell, M. J.; Radisky, D. C. Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb. Perspect. Biol. 2012, 4(2), pii: a011908.
133. Daskalopoulos, E. P.; Janssen, B. J.; Blankesteijn, W. M. Myofibroblasts in the infarct area: concepts and challenges. Microsc. Microanal. 2012, 18(1), 35-49.
134. Su, H.; Spinale, F. G.; Dobrucki, L. W.; Song, J.; Hua, J.; Sweterlitsch, S.; Dione, D. P.; Cavaliere, P.; Chow, C.; Bourke, B. N.; Hu, X. Y.; Azure, M.; Yalamanchili, P.; Liu, R.; Cheesman, E. H.; Robinson, S.; Edwards, D. S.; Sinusas, A. J. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005, 112(20), 3157-67.
135. Yarbrough, W. M.; Mukherjee, R.; Escobar, G. P.; Mingoia, J. T.; Sample, J. A.; Hendrick, J. W.; Dowdy, K. B.; McLean, J. E.; Lowry, A. S.; O'Neill, T. P.; Spinale, F. G. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003, 108(14), 1753-9.
136. Sahul, Z. H.; Mukherjee, R.; Song, J.; McAteer, J.; Stroud, R. E.; Dione, D. P.; Staib, L.; Papademetris, X.; Dobrucki, L. W.; Duncan, J. S.; Spinale, F. G.; Sinusas, A. J. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ. Cardiovasc. Imaging 2011, 4(4), 381-91.
137. Cleutjens, J. P.; Verluyten, M. J.; Smiths, J. F.; Daemen, M. J. Collagen remodeling after myocardial infarction in the rat heart. Am. J. Pathol. 1995, 147(2), 325-38.
138. Weber, K. T.; Anversa, P.; Armstrong, P. W.; Brilla, C. G.; Burnett, J. C. Jr.; Cruickshank, J. M.; Devereux, R. B.; Giles, T. D.; Korsgaard, N.; Leier, C. V.; et al. Remodeling and reparation of the cardiovascular system. J. Am. Coll. Cardiol. 1992, 20(1), 3-16.
139. Wilson, E. M.; Moainie, S. L.; Baskin, J. M.; Lowry, A. S.; Deschamps, A. M.; Mukherjee, R.; Guy, T. S.; St John-Sutton, M. G.; Gorman, J. H. 3rd; Edmunds, L. H. Jr.; Gorman, R. C.; Spinale, F. G. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003, 107(22), 2857-63.
140. Spinale, F. G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 2007, 87(4), 1285-342.
141. Spinale, F. G.; Janicki, J. S.; Zile, M. R. Membrane-associated matrix proteolysis and heart failure. Circ. Res. 2013, 112(1), 195-208.
142. Kassiri, Z.; Defamie, V.; Hariri, M.; Oudit, G. Y.; Anthwal, S.; Dawood, F.; Liu, P.; Khokha, R. Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J. Biol. Chem. 2009, 284(43), 29893-904.
143. Ducharme, A.; Frantz, S.; Aikawa, M.; Rabkin, E.; Lindsey, M.; Rohde, L. E.; Schoen, F. J.; Kelly, R. A.; Werb, Z.; Libby, P.; Lee, R. T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 2000, 106(1), 55-62.
144. Matsumura, S.; Iwanaga, S.; Mochizuki, S.; Okamoto, H.; Ogawa, S.; Okada, Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J. Clin. Invest. 2005, 115(3), 599-609.
145. Lindsey, M. L.; Escobar, G. P.; Mukherjee, R.; Goshorn, D. K.; Sheats, N. J.; Bruce, J. A.; Mains, I. M.; Hendrick, J. K.; Hewett, K. W.; Gourdie, R. G.; Matrisian, L. M.; Spinale, F. G. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 2006, 113(25), 2919-28.
146. Lindsey, M. L.; Escobar, G. P.; Dobrucki, L. W.; Goshorn, D. K.; Bouges, S.; Mingoia, J. T.; McClister, D. M. Jr.; Su, H.; Gannon, J.; MacGillivray, C.; Lee, R. T.; Sinusas, A. J.; Spinale, F. G. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(1), H232-9.
147. Lopez, B.; Gonzalez, A.; Querejeta, R.; Larman, M.; Diez, J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J. Am. Coll. Cardiol. 2006, 48(1), 89-96.
148. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Conlon, C.; Patle, A.; Donnelly, S. C.; McDonald, K. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115(7), 888-95.
149. Weidemann, F.; Herrmann, S.; Stork, S.; Niemann, M.; Frantz, S.; Lange, V.; Beer, M.; Gattenlohner, S.; Voelker, W.; Ertl, G.; Strotmann, J. M. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009, 120(7), 577-84.
150. Ahmed, S. H.; Clark, L. L.; Pennington, W. R.; Webb, C. S.; Bonnema, D. D.; Leonardi, A. H.; McClure, C. D.; Spinale, F. G.; Zile, M. R. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113(17), 2089-96.
151. Marchesi, C.; Dentali, F.; Nicolini, E.; Maresca, A. M.; Tayebjee, M. H.; Franz, M.; Guasti, L.; Venco, A.; Schiffrin, E. L.; Lip, G. Y.; Grandi, A. M. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and metaanalysis. J. Hypertens. 2012, 30(1), 3-16.
152. Mak, G. J.; Ledwidge, M. T.; Watson, C. J.; Phelan, D. M.; Dawkins, I. R.; Murphy, N. F.; Patle, A. K.; Baugh, J. A.; McDonald, K. M. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 2009, 54(18), 1674-82.
153. Heymans, S.; Schroen, B.; Vermeersch, P.; Milting, H.; Gao, F.; Kassner, A.; Gillijns, H.; Herijgers, P.; Flameng, W.; Carmeliet, P.; Van De Werf, F.; Pinto, Y. M.; Janssens, S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005, 112(8), 1136-44.
154. Polyakova, V.; Hein, S.; Kostin, S.; Ziegelhoeffer, T.; Schaper, J. Matrix metalloproteinases and their tissue inhibitors in pressureoverloaded human myocardium during heart failure progression. J. Am. Coll. Cardiol. 2004, 44(8), 1609-18.
155. Yarbrough, W. M.; Mukherjee, R.; Stroud, R. E.; Rivers, W. T.; Oelsen, J. M.; Dixon, J. A.; Eckhouse, S. R.; Ikonomidis, J. S.; Zile, M. R.; Spinale, F. G. Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J. Thorac. Cardiovasc. Surg. 2012, 143(1), 215-23.
156. Nagatomo, Y.; Carabello, B. A.; Coker, M. L.; McDermott, P. J.; Nemoto, S.; Hamawaki, M.; Spinale, F. G. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am. J. Physiol. Heart Circ. Physiol. 2000, 278(1), H151-61.
157. Stewart, J. A. Jr.; Wei, C. C.; Brower, G. L.; Rynders, P. E.; Hankes, G. H.; Dillon, A. R.; Lucchesi, P. A.; Janicki, J. S.; Dell'Italia, L. J. Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J. Mol. Cell. Cardiol. 2003, 35(3), 311-9.
158. Thomas, C. V.; Coker, M. L.; Zellner, J. L.; Handy, J. R.; Crumbley, A. J. 3rd; Spinale, F. G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97(17), 1708-15.
159. Gladka, M. M.; Da Costa Martins, P. A.; De Windt, L. J. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J. Mol. Cell. Cardiol. 2012, 52(1), 74-82.
160. Castro, M. M.; Tanus-Santos, J. E.; Gerlach, R. F. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol. Res. 2011, 64(6), 567-72.
161. Lovett, D. H.; Mahimkar, R.; Raffai, R. L.; Cape, L.; Maklashina, E.; Cecchini, G.; Karliner, J. S. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 2012, 7(4), e34177.
162. Gonzalez, A.; Lopez, B.; Querejeta, R.; Zubillaga, E.; Echeverria, T.; Diez, J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010, 55(6), 1418-24.
163. Zile, M. R.; Desantis, S. M.; Baicu, C. F.; Stroud, R. E.; Thompson, S. B.; McClure, C. D.; Mehurg, S. M.; Spinale, F. G. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ. Heart Fail. 2011, 4(3), 246-56.
164. Westermann, D.; Lindner, D.; Kasner, M.; Zietsch, C.; Savvatis, K.; Escher, F.; Von Schlippenbach, J.; Skurk, C.; Steendijk, P.; Riad, A.; Poller, W.; Schultheiss, H. P.; Tschope, C. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ. Heart Fail. 2011, 4(1), 44-52.
165. Limb, G. A.; Matter, K.; Murphy, G.; Cambrey, A. D.; Bishop, P. N.; Morris, G. E.; Khaw, P. T. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am. J. Pathol. 2005, 166(5), 1555-63.
166. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Murphy, N. F.; Conlon, C.; Patle, A.; Donnelly, S. C.; McDonald, K. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur. J. Heart Fail. 2009, 11(2), 191-7.
167. Manhenke, C.; Orn, S.; Squire, I.; Radauceanu, A.; Alla, F.; Zannad, F.; Dickstein, K. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int. J. Cardiol. 2011, 150(3), 277-82.
168. Orn, S.; Manhenke, C.; Squire, I. B.; Ng, L.; Anand, I.; Dickstein, K. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J. Card. Fail. 2007, 13(10), 843-9.
169. Kelly, D.; Khan, S. Q.; Thompson, M.; Cockerill, G.; Ng, L. L.; Samani, N.; Squire, I. B. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur. Heart J. 2008, 29(17), 2116-24.
170. Radauceanu, A.; Ducki, C.; Virion, J. M.; Rossignol, P.; Mallat, Z.; McMurray, J.; Van Veldhuisen, D. J.; Tavazzi, L.; Mann, D. L.; Capiaumont-Vin, J.; Li, M.; Hanriot, D.; Zannad, F. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J. Card. Fail. 2008, 14(6), 467-74.
171. Fertin, M.; Dubois, E.; Belliard, A.; Amouyel, P.; Pinet, F.; Bauters, C. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am. J. Cardiol. 2012, 110(2), 277-83.
172. Krakauer, T. Nuclear factor-kappaB: fine-tuning a central integrator of diverse biologic stimuli. Int. Rev. Immunol. 2008, 27(5), 286-92.
173. Roysland, R.; Masson, S.; Omland, T.; Milani, V.; Bjerre, M.; Flyvbjerg, A.; Di Tano, G.; Misuraca, G.; Maggioni, A. P.; Tognoni, G.; Tavazzi, L.; Latini, R. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am. Heart J. 2010, 160(2), 286-93.
174. Ueland, T.; Dahl, C. P.; Kjekshus, J.; Hulthe, J.; Bohm, M.; Mach, F.; Goudev, A.; Lindberg, M.; Wikstrand, J.; Aukrust, P.; Gullestad, L. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ. Heart Fail. 2011, 4(2), 145-52.
175. Feng, W.; Li, W.; Liu, W.; Wang, F.; Li, Y.; Yan, W. IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp. Mol. Pathol. 2009, 87(3), 212-8.
176. De Boer, R. A.; Voors, A. A.; Muntendam, P.; Van Gilst, W. H.; Van Veldhuisen, D. J. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 2009, 11(9), 811-7.
177. Gabius, H. J. Cell surface glycans: the why and how of their functionality as biochemical signals in lectin-mediated information transfer. Crit. Rev. Immunol. 2006, 26(1), 43-79.
178. Toprak, G.; Yuksel, H.; Demirpence, O.; Islamoglu, Y.; Evliyaoglu, O.; Mete, N. Fibrosis in heart failure subtypes. Eur. Rev. Med. Pharmacol. Sci. 2013, 17(17), 2302-9.
179. Van Der Velde, A. R.; Gullestad, L.; Ueland, T.; Aukrust, P.; Guo, Y.; Adourian, A.; Muntendam, P.; Van Veldhuisen, D. J.; De Boer, R. A. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ. Heart Fail. 2013, 6(2), 219-26.
180. Ahmad, T.; Fiuzat, M.; Felker, G. M.; O'Connor, C. Novel biomarkers in chronic heart failure. Nat. Rev. Cardiol. 2012, 9(6), 347-59.
181. Felker, G. M.; Fiuzat, M.; Shaw, L. K.; Clare, R.; Whellan, D. J.; Bettari, L.; Shirolkar, S. C.; Donahue, M.; Kitzman, D. W.; Zannad, F.; Pina, I. L.; O'Connor, C. M. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ. Heart Fail. 2012, 5(1), 72-8.
182. Olson, T. S.; Ley, K. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 283(1), R7-28.
183. Clark-Lewis, I.; Kim, K. S.; Rajarathnam, K.; Gong, J. H.; Dewald, B.; Moser, B.; Baggiolini, M.; Sykes, B. D. Structure-activity relationships of chemokines. J. Leukoc. Biol. 1995, 57(5), 703-11.
184. Rollins, B. J.; Yoshimura, T.; Leonard, E. J.; Pober, J. S. Cytokineactivated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am. J. Pathol. 1990, 136(6), 1229-33.
185. Aukrust, P.; Ueland, T.; Muller, F.; Andreassen, A. K.; Nordoy, I.; Aas, H.; Kjekshus, J.; Simonsen, S.; Froland, S. S.; Gullestad, L. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998, 97(12), 1136-43.
186. Strieter, R. M.; Polverini, P. J.; Arenberg, D. A.; Walz, A.; Opdenakker, G.; Van Damme, J.; Kunkel, S. L. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukoc. Biol. 1995, 57(5), 752-62.
187. Dobaczewski, M.; Frangogiannis, N. G. Chemokines and cardiac fibrosis. Front Biosci (Schol Ed) 2009, 1, 391-405.
188. Damas, J. K.; Eiken, H. G.; Oie, E.; Bjerkeli, V.; Yndestad, A.; Ueland, T.; Tonnessen, T.; Geiran, O. R.; Aass, H.; Simonsen, S.; Christensen, G.; Froland, S. S.; Attramadal, H.; Gullestad, L.; Aukrust, P. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc. Res. 2000, 47(4), 778-87.
189. Damas, J. K.; Gullestad, L.; Ueland, T.; Solum, N. O.; Simonsen, S.; Froland, S. S.; Aukrust, P. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc. Res. 2000, 45(2), 428-36.
190. Braunersreuther, V.; Montecucco, F.; Pelli, G.; Galan, K.; Proudfoot, A. E.; Belin, A.; Vuilleumier, N.; Burger, F.; Lenglet, S.; Caffa, I.; Soncini, D.; Nencioni, A.; Vallee, J. P.; Mach, F. Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb. Haemost. 2013, 110(4), 807-25.
191. Majmudar, M. D.; Keliher, E. J.; Heidt, T.; Leuschner, F.; Truelove, J.; Sena, B. F.; Gorbatov, R.; Iwamoto, Y.; Dutta, P.; Wojtkiewicz, G.; Courties, G.; Sebas, M.; Borodovsky, A.; Fitzgerald, K.; Nolte, M. W.; Dickneite, G.; Chen, J. W.; Anderson, D. G.; Swirski, F. K.; Weissleder, R.; Nahrendorf, M. Monocytedirected RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation 2013, 127(20), 2038-46.
192. Zhao, G.; Wang, S.; Wang, Z.; Sun, A.; Yang, X.; Qiu, Z.; Wu, C.; Zhang, W.; Li, H.; Zhang, Y.; Zhao, J.; Zou, Y.; Ge, J. CXCR6 deficiency ameliorated myocardial ischemia/reperfusion injury by inhibiting infiltration of monocytes and IFN-gamma-dependent autophagy. Int. J. Cardiol. 2013, 168(2), 853-62.
193. Larocca, T. J.; Jeong, D.; Kohlbrenner, E.; Lee, A.; Chen, J.; Hajjar, R. J.; Tarzami, S. T. CXCR4 gene transfer prevents pressure overload induced heart failure. J. Mol. Cell. Cardiol. 2012, 53(2), 223-32.
194. Montecucco, F.; Braunersreuther, V.; Lenglet, S.; Delattre, B. M.; Pelli, G.; Buatois, V.; Guilhot, F.; Galan, K.; Vuilleumier, N.; Ferlin, W.; Fischer, N.; Vallee, J. P.; Kosco-Vilbois, M.; Mach, F. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur. Heart J. 2012, 33(15), 1964-74.
195. Kalogeropoulos, A.; Georgiopoulou, V.; Psaty, B. M.; Rodondi, N.; Smith, A. L.; Harrison, D. G.; Liu, Y.; Hoffmann, U.; Bauer, D. C.; Newman, A. B.; Kritchevsky, S. B.; Harris, T. B.; Butler, J. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J. Am. Coll. Cardiol. 2010, 55(19), 2129-37.
196. Suzuki, S.; Takeishi, Y.; Niizeki, T.; Koyama, Y.; Kitahara, T.; Sasaki, T.; Sagara, M.; Kubota, I. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am. Heart J. 2008, 155(1), 75-81.
197. Harutyunyan, M.; Christiansen, M.; Johansen, J. S.; Kober, L.; Torp-Petersen, C.; Kastrup, J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 2012, 217(6), 652-6.
198. Yndestad, A.; Damas, J. K.; Geir Eiken, H.; Holm, T.; Haug, T.; Simonsen, S.; Froland, S. S.; Gullestad, L.; Aukrust, P. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc. Res. 2002, 54(1), 175-82.
199. Yndestad, A.; Ueland, T.; Oie, E.; Florholmen, G.; Halvorsen, B.; Attramadal, H.; Simonsen, S.; Froland, S. S.; Gullestad, L.; Christensen, G.; Damas, J. K.; Aukrust, P. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004, 109(11), 1379-85.
200. Dixon, D. L.; Griggs, K. M.; Bersten, A. D.; De Pasquale, C. G. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine 2011, 56(3), 593-9.
201. Kotby, A. A.; Abdel Aziz, M. M.; El Guindy, W. M.; Moneer, A. N. Can serum tenascin-C be used as a marker of inflammation in patients with dilated cardiomyopathy? Int. J. Pediatr. 2013, 2013, 608563.
202. Niessner, A.; Hohensinner, P. J.; Rychli, K.; Neuhold, S.; Zorn, G.; Richter, B.; Hulsmann, M.; Berger, R.; Mortl, D.; Huber, K.; Wojta, J.; Pacher, R. Prognostic value of apoptosis markers in advanced heart failure patients. Eur. Heart J. 2009, 30(7), 789-96.
203. Li, Y.; Takemura, G.; Kosai, K.; Takahashi, T.; Okada, H.; Miyata, S.; Yuge, K.; Nagano, S.; Esaki, M.; Khai, N. C.; Goto, K.; Mikami, A.; Maruyama, R.; Minatoguchi, S.; Fujiwara, T.; Fujiwara, H. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ. Res. 2004, 95(6), 627-36.
204. Doni, A.; Peri, G.; Chieppa, M.; Allavena, P.; Pasqualini, F.; Vago, L.; Romani, L.; Garlanda, C.; Mantovani, A. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur. J. Immunol. 2003, 33(10), 2886-93.
205. Matsubara, J.; Sugiyama, S.; Nozaki, T.; Sugamura, K.; Konishi, M.; Ohba, K.; Matsuzawa, Y.; Akiyama, E.; Yamamoto, E.; Sakamoto, K.; Nagayoshi, Y.; Kaikita, K.; Sumida, H.; Kim-Mitsuyama, S.; Ogawa, H. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J. Am. Coll. Cardiol. 2011, 57(7), 861-9.
206. Duran, S.; Duran, I.; Kaptanagasi, F. A.; Nartop, F.; Ciftci, H.; Korkmaz, G. G. The role of pentraxin 3 as diagnostic value in classification of patients with heart failure. Clin. Biochem. 2013, 46(12), 983-7.
207. Volck, B.; Price, P. A.; Johansen, J. S.; Sorensen, O.; Benfield, T. L.; Nielsen, H. J.; Calafat, J.; Borregaard, N. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc. Assoc. Am. Physicians 1998, 110(4), 351-60.
208. Yndestad, A.; Holm, A. M.; Muller, F.; Simonsen, S.; Froland, S. S.; Gullestad, L.; Aukrust, P. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc. Res. 2003, 60(1), 141-6.
209. Secchiero, P.; Corallini, F.; Beltrami, A. P.; Ceconi, C.; Bonasia, V.; Di Chiara, A.; Ferrari, R.; Zauli, G. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010, 210(1), 274-7.
210. Sanderson, J. E.; Lai, K. B.; Shum, I. O.; Wei, S.; Chow, L. T. Transforming growth factor-beta (1) expression in dilated cardiomyopathy. Heart 2001, 86(6), 701-8.
211. Jones, F. S.; Jones, P. L. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev. Dyn. 2000, 218(2), 235-59.
212. Imanaka-Yoshida, K.; Hiroe, M.; Nishikawa, T.; Ishiyama, S.; Shimojo, T.; Ohta, Y.; Sakakura, T.; Yoshida, T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab. Invest. 2001, 81(7), 1015-24.
213. Frangogiannis, N. G.; Shimoni, S.; Chang, S. M.; Ren, G.; Dewald, O.; Gersch, C.; Shan, K.; Aggeli, C.; Reardon, M.; Letsou, G. V.; Espada, R.; Ramchandani, M.; Entman, M. L.; Zoghbi, W. A. Active interstitial remodeling: an important process in the hibernating human myocardium. J. Am. Coll. Cardiol. 2002, 39(9), 1468-74.
214. Le, D. E.; Pascotto, M.; Leong-Poi, H.; Sari, I.; Micari, A.; Kaul, S. Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res. Cardiol. 2013, 108(6), 384.
215. Kurum, T.; Tatli, E.; Yuksel, M. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Tex. Heart Inst. J. 2007, 34(1), 52-9.
216. Alfieri, A. B.; Briceno, L.; Fragasso, G.; Spoladore, R.; Palloshi, A.; Bassanelli, G.; Montano, C.; Arioli, F.; Cuko, A.; Ruotolo, G.; Margonato, A. Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. J. Cardiovasc. Pharmacol. 2008, 52(1), 49-54.
217. Gullestad, L.; Ueland, T.; Brunsvig, A.; Kjekshus, J.; Simonsen, S.; Froland, S. S.; Aukrust, P. Effect of metoprolol on cytokine levels in chronic heart failure-a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am. Heart J. 2001, 141(3), 418-21.
218. Ohtsuka, T.; Hamada, M.; Hiasa, G.; Sasaki, O.; Suzuki, M.; Hara, Y.; Shigematsu, Y.; Hiwada, K. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001, 37(2), 412-7.
219. Ogino, K.; Kato, M.; Furuse, Y.; Kinugasa, Y.; Kaetsu, Y.; Mizuta, E.; Sugihara, S.; Ishida, K.; Yanagihara, K.; Hisatome, I.; Shigemasa, C. Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without beta-blockers. Circ. J. 2010, 74(11), 2346-52.
220. Tsutamoto, T.; Wada, A.; Maeda, K.; Mabuchi, N.; Hayashi, M.; Tsutsui, T.; Ohnishi, M.; Sawaki, M.; Fujii, M.; Matsumoto, T.; Kinoshita, M. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J. Am. Coll. Cardiol. 2000, 35(3), 714-21.
221. Anand, I. S.; Latini, R.; Florea, V. G.; Kuskowski, M. A.; Rector, T.; Masson, S.; Signorini, S.; Mocarelli, P.; Hester, A.; Glazer, R.; Cohn, J. N.; Val-He, F. T. I. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005, 112(10), 1428-34.
222. Sukumaran, V.; Veeraveedu, P. T.; Gurusamy, N.; Yamaguchi, K.; Lakshmanan, A. P.; Ma, M.; Suzuki, K.; Kodama, M.; Watanabe, K. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int. J. Biol. Sci. 2011, 7(8), 1077-92.
223. Sukumaran, V.; Veeraveedu, P. T.; Gurusamy, N.; Lakshmanan, A. P.; Yamaguchi, K.; Ma, M.; Suzuki, K.; Nagata, M.; Takagi, R.; Kodama, M.; Watanabe, K. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol. Cell. Endocrinol. 2012, 351(2), 208-19.
224. Gullestad, L.; Aukrust, P.; Ueland, T.; Espevik, T.; Yee, G.; Vagelos, R.; Froland, S. S.; Fowler, M. Effect of high-versus lowdose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol. 1999, 34(7), 2061-7.
225. Lahera, V.; Cachofeiro, V.; Balfagon, G.; Rodicio, J. L. Aldosterone and its blockade: a cardiovascular and renal perspective. ScientificWorldJournal 2006, 6, 413-24.
226. Macdonald, J. E.; Kennedy, N.; Struthers, A. D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004, 90(7), 765-70.
227. Yee, K. M.; Pringle, S. D.; Struthers, A. D. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J. Am. Coll. Cardiol. 2001, 37(7), 1800-7.
228. Farquharson, C. A.; Struthers, A. D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101(6), 594-7.
229. Godfrey, V.; Farquharson, C. A.; Macdonald, J. E.; Yee, K. M.; Struthers, A. D. Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int. J. Cardiol. 2007, 117(2), 282-4.
230. Pinsky, D. J.; Cai, B.; Yang, X.; Rodriguez, C.; Sciacca, R. R.; Cannon, P. J. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J. Clin. Invest. 1995, 95(2), 677-85.
231. Pahan, K.; Sheikh, F. G.; Namboodiri, A. M.; Singh, I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 1997, 100(11), 2671-9.
232. Rosenson, R. S.; Tangney, C. C.; Casey, L. C. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999, 353(9157), 983-4.
233. Grip, O.; Janciauskiene, S.; Lindgren, S. Pravastatin downregulates inflammatory mediators in human monocytes in vitro. Eur. J. Pharmacol. 2000, 410(1), 83-92.
234. Casey, P. J. Protein lipidation in cell signaling. Science 1995, 268(5208), 221-5.
235. Hilgendorff, A.; Muth, H.; Parviz, B.; Staubitz, A.; Haberbosch, W.; Tillmanns, H.; Holschermann, H. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int. J. Clin. Pharmacol. Ther. 2003, 41(9), 397-401.
236. Laufs, U.; La Fata, V.; Plutzky, J.; Liao, J. K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97(12), 1129-35.
237. Von Haehling, S.; Anker, S. D.; Bassenge, E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail. Rev. 2003, 8(1), 99-106.
238. Vaughan, C. J.; Murphy, M. B.; Buckley, B. M. Statins do more than just lower cholesterol. Lancet 1996, 348(9034), 1079-82.
239. Hernandez-Perera, O.; Perez-Sala, D.; Navarro-Antolin, J.; Sanchez-Pascuala, R.; Hernandez, G.; Diaz, C.; Lamas, S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 1998, 101(12), 2711-9.
240. Katz, S. D.; Khan, T.; Zeballos, G. A.; Mathew, L.; Potharlanka, P.; Knecht, M.; Whelan, J. Decreased activity of the L-argininenitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999, 99(16), 2113-7.
241. Williams, J. K.; Sukhova, G. K.; Herrington, D. M.; Libby, P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 1998, 31(3), 684-91.
242. Jones, S. P.; Greer, J. J.; Kakkar, A. K.; Ware, P. D.; Turnage, R. H.; Hicks, M.; Van Haperen, R.; De Crom, R.; Kawashima, S.; Yokoyama, M.; Lefer, D. J. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2004, 286(1), H276-82.
243. Jones, S. P.; Greer, J. J.; Van Haperen, R.; Duncker, D. J.; De Crom, R.; Lefer, D. J. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(8), 4891-6.
244. Vasquez-Vivar, J.; Kalyanaraman, B.; Martasek, P.; Hogg, N.; Masters, B. S.; Karoui, H.; Tordo, P.; Pritchard, K. A. Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(16), 9220-5.
245. Juncos, L. I.; Juncos, L. A.; Garcia, N. H. The antihypertensive actions of statins: modulation by salt intake. Am. J. Hypertens. 2012, 25(11), 1140-8.
246. Juncos, L. I.; Martin, F. L.; Baigorria, S. T.; Pasqualini, M. E.; Fiore, M. C.; Eynard, A. R.; Juncos, L. A.; Garcia, N. H. Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency. Nutrition 2012, 28(9), e23-8.
247. Nomura, S.; Yoshimura, K.; Akiyama, N.; Mikamo, A.; Furutani, A.; Aoki, H.; Matsuzaki, M.; Hamano, K. HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Eur. Surg. Res. 2005, 37(6), 370-8.
248. Luan, Z.; Chase, A. J.; Newby, A. C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol. 2003, 23(5), 769-75.
249. Sharma, U. C.; Pokharel, S.; Van Brakel, T. J.; Van Berlo, J. H.; Cleutjens, J. P.; Schroen, B.; Andre, S.; Crijns, H. J.; Gabius, H. J.; Maessen, J.; Pinto, Y. M. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110(19), 3121-8.
250. Sola, S.; Mir, M. Q.; Rajagopalan, S.; Helmy, T.; Tandon, N.; Khan, B. V. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J. Card. Fail. 2005, 11(8), 607-12.
251. Wojnicz, R.; Wilczek, K.; Nowalany-Kozielska, E.; Szygula-Jurkiewicz, B.; Nowak, J.; Polonski, L.; Dyrbus, K.; Badzinski, A.; Mercik, G.; Zembala, M.; Wodniecki, J.; Rozek, M. M. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am. J. Cardiol. 2006, 97(6), 899-904.
252. Yamada, T.; Node, K.; Mine, T.; Morita, T.; Kioka, H.; Tsukamoto, Y.; Tamaki, S.; Masuda, M.; Okuda, K.; Fukunami, M. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am. Heart J. 2007, 153(6), 1055 e1-8.
253. Node, K. [Aging of cardiovascular system and female hormone-heart failure and estrogen]. Nihon Ronen Igakkai Zasshi 2003, 40(4), 332-5.
254. Bleske, B. E.; Nicklas, J. M.; Bard, R. L.; Brook, R. D.; Gurbel, P. A.; Bliden, K. P.; Rajagopalan, S.; Pitt, B. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J. Am. Coll. Cardiol. 2006, 47(2), 338-41.
255. Tousoulis, D.; Andreou, I.; Tsiatas, M.; Miliou, A.; Tentolouris, C.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C. A.; Dimopoulos, M. A.; Stefanadis, C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis 2011, 214(1), 151-7.
256. Andreou, I.; Tousoulis, D.; Miliou, A.; Tentolouris, C.; Zisimos, K.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C. A.; Dimopoulos, M. A.; Stefanadis, C. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 2010, 210(1), 194-8.
257. Tousoulis, D.; Andreou, I.; Tentolouris, C.; Antoniades, C.; Papageorgiou, N.; Gounari, P.; Kotrogiannis, I.; Miliou, A.; Charakida, M.; Trikas, A.; Stefanadis, C. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int. J. Cardiol. 2010, 145(3), 438-43.
258. Bielecka-Dabrowa, A.; Goch, J. H.; Mikhailidis, D. P.; Rysz, J.; Maciejewski, M.; Banach, M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med. Sci. Monit. 2009, 15(12), MS12-23.
259. Horwich, T. B.; Middlekauff, H. R.; Maclellan, W. R.; Fonarow, G. C. Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J. Card. Fail. 2011, 17(11), 879-86.
260. Krum, H.; Ashton, E.; Reid, C.; Kalff, V.; Rogers, J.; Amarena, J.; Singh, B.; Tonkin, A. Double-blind, randomized, placebocontrolled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J. Card. Fail. 2007, 13(1), 1-7.
261. Abulhul, E.; McDonald, K.; Martos, R.; Phelan, D.; Spiers, J. P.; Hennessy, M.; Baugh, J.; Watson, C.; O'Loughlin, C.; Ledwidge, M. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin. Ther. 2012, 34(1), 91-100.
262. Mozaffarian, D.; Minami, E.; Letterer, R. A.; Lawler, R. L.; McDonald, G. B.; Levy, W. C. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am. J. Cardiol. 2005, 96(12), 1699-704.
263. Castro, P. F.; Miranda, R.; Verdejo, H. E.; Greig, D.; Gabrielli, L. A.; Alcaino, H.; Chiong, M.; Bustos, C.; Garcia, L.; Mellado, R.; Vukasovic, J. L.; Godoy, I.; Lavandero, S. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J. Heart Lung Transplant. 2008, 27(4), 435-41.
264. Tsutamoto, T.; Sakai, H.; Ibe, K.; Yamaji, M.; Kawahara, C.; Nakae, I.; Fujii, M.; Yamamoto, T.; Horie, M. Effect of atorvastatin vs.rosuvastatin on cardiac sympathetic nerve activity in nondiabetic patients with dilated cardiomyopathy. Circ. J. 2011, 75(9), 2160-6.
265. Kjekshus, J.; Apetrei, E.; Barrios, V.; Bohm, M.; Cleland, J. G.; Cornel, J. H.; Dunselman, P.; Fonseca, C.; Goudev, A.; Grande, P.; Gullestad, L.; Hjalmarson, A.; Hradec, J.; Janosi, A.; Kamensky, G.; Komajda, M.; Korewicki, J.; Kuusi, T.; Mach, F.; Mareev, V.; McMurray, J. J.; Ranjith, N.; Schaufelberger, M.; Vanhaecke, J.; Van Veldhuisen, D. J.; Waagstein, F.; Wedel, H.; Wikstrand, J. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007, 357(22), 2248-61.
266. Gissi, H. F. I.; Tavazzi, L.; Maggioni, A. P.; Marchioli, R.; Barlera, S.; Franzosi, M. G.; Latini, R.; Lucci, D.; Nicolosi, G. L.; Porcu, M.; Tognoni, G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645), 1231-9.
267. Yancy, C. W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D. E. Jr.; Drazner, M. H.; Fonarow, G. C.; Geraci, S. A.; Horwich, T.; Januzzi, J. L.; Johnson, M. R.; Kasper, E. K.; Levy, W. C.; Masoudi, F. A.; McBride, P. E.; McMurray, J. J.; Mitchell, J. E.; Peterson, P. N.; Riegel, B.; Sam, F.; Stevenson, L. W.; Tang, W. H.; Tsai, E. J.; Wilkoff, B. L. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128(16), 1810-52.
268. Lyons, K. S.; McVeigh, G. E.; Harbinson, M. T. Statins in heart failure-where do we stand? Cardiovasc. Drugs Ther. 2011, 25(1), 99-104.
269. Bozkurt, B.; Kribbs, S. B.; Clubb, F. J. Jr.; Michael, L. H.; Didenko, V. V.; Hornsby, P. J.; Seta, Y.; Oral, H.; Spinale, F. G.; Mann, D. L. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97(14), 1382-91.
270. Bryant, D.; Becker, L.; Richardson, J.; Shelton, J.; Franco, F.; Peshock, R.; Thompson, M.; Giroir, B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998, 97(14), 1375-81.
271. Mann, D. L.; McMurray, J. J.; Packer, M.; Swedberg, K.; Borer, J. S.; Colucci, W. S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; Krum, H.; Liu, P.; Nieminen, M.; Tavazzi, L.; Van Veldhuisen, D. J.; Waldenstrom, A.; Warren, M.; Westheim, A.; Zannad, F.; Fleming, T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109(13), 1594-602.
272. Chung, E. S.; Packer, M.; Lo, K. H.; Fasanmade, A. A.; Willerson, J. T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107(25), 3133-40.
273. Wojnicz, R.; Nowalany-Kozielska, E.; Wojciechowska, C.; Glanowska, G.; Wilczewski, P.; Niklewski, T.; Zembala, M.; Polonski, L.; Rozek, M. M.; Wodniecki, J. Randomized, placebocontrolled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001, 104(1), 39-45.
274. Gullestad, L.; Semb, A. G.; Holt, E.; Skardal, R.; Ueland, T.; Yndestad, A.; Froland, S. S.; Aukrust, P. Effect of thalidomide in patients with chronic heart failure. Am. Heart J. 2002, 144(5), 847-50.
275. Gullestad, L.; Ueland, T.; Fjeld, J. G.; Holt, E.; Gundersen, T.; Breivik, K.; Folling, M.; Hodt, A.; Skardal, R.; Kjekshus, J.; Andreassen, A.; Kjekshus, E.; Wergeland, R.; Yndestad, A.; Froland, S. S.; Semb, A. G.; Aukrust, P. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a doubleblind, placebo-controlled study. Circulation 2005, 112(22), 3408-14.
276. Sliwa, K.; Woodiwiss, A.; Kone, V. N.; Candy, G.; Badenhorst, D.; Norton, G.; Zambakides, C.; Peters, F.; Essop, R. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004, 109(6), 750-5.
277. Skudicky, D.; Bergemann, A.; Sliwa, K.; Candy, G.; Sareli, P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001, 103(8), 1083-8.
278. Bahrmann, P.; Hengst, U. M.; Richartz, B. M.; Figulla, H. R. Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. Eur. J. Heart Fail. 2004, 6(2), 195-201.
279. Xin, W.; Wei, W.; Li, X. Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord. 2012, 12, 77.
280. Tavazzi, L.; Maggioni, A. P.; Marchioli, R.; Barlera, S.; Franzosi, M. G.; Latini, R.; Lucci, D.; Nicolosi, G. L.; Porcu, M.; Tognoni, G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645), 1223-30.
281. Gong, K. Z.; Song, G.; Spiers, J. P.; Kelso, E. J.; Zhang, Z. G. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. Int. J. Clin. Pract. 2007, 61(4), 611-21.
282. Moreira, D. M.; Vieira, J. L.; Gottschall, C. A. The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebocontrolled trial (METIS trial). J. Card. Fail. 2009, 15(10), 828-34.
283. Gong, K.; Zhang, Z.; Sun, X.; Zhang, X.; Li, A.; Yan, J.; Luo, Q.; Gao, Y.; Feng, Y. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am. Heart J. 2006, 151(1), 62-8.
284. Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Raisakis, K.; Bouras, G.; Angelidis, C.; Theodorakis, A.; Driva, M.; Doudoumis, K.; Pyrgakis, V.; Stefanadis, C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol. 2012, 60(18), 1790-6.
285. Deftereos, S.; Giannopoulos, G.; Raisakis, K.; Kossyvakis, C.; Kaoukis, A.; Panagopoulou, V.; Driva, M.; Hahalis, G.; Pyrgakis, V.; Alexopoulos, D.; Manolis, A. S.; Stefanadis, C.; Cleman, M. W. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J. Am. Coll. Cardiol. 2013, 61(16), 1679-85.
286. Nidorf, S. M.; Eikelboom, J. W.; Budgeon, C. A.; Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013, 61(4), 404-10.
287. Imazio, M.; Brucato, A.; Ferrazzi, P.; Rovere, M. E.; Gandino, A.; Cemin, R.; Ferrua, S.; Belli, R.; Maestroni, S.; Simon, C.; Zingarelli, E.; Barosi, A.; Sansone, F.; Patrini, D.; Vitali, E.; Trinchero, R.; Spodick, D. H.; Adler, Y.; Investigators, C. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation 2011, 124(21), 2290-5.
288. Deftereos, S.; Giannopoulos, G.; Panagopoulou, V.; Bouras, G.; Raisakis, K.; Kossyvakis, C.; Karageorgiou, S.; Papadimitriou, C.; Vastaki, M.; Kaoukis, A.; Angelidis, C.; Pagoni, S.; Pyrgakis, V.; Alexopoulos, D.; Manolis, A. S.; Stefanadis, C.; Cleman, M. W. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014, 2(2), 131-7.
289. Deswal, A.; Bozkurt, B.; Seta, Y.; Parilti-Eiswirth, S.; Hayes, F. A.; Blosch, C.; Mann, D. L. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99(25), 3224-6.
290. Bozkurt, B.; Torre-Amione, G.; Warren, M. S.; Whitmore, J.; Soran, O. Z.; Feldman, A. M.; Mann, D. L. Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001, 103(8), 1044-7.
291. Parrillo, J. E.; Cunnion, R. E.; Epstein, S. E.; Parker, M. M.; Suffredini, A. F.; Brenner, M.; Schaer, G. L.; Palmeri, S. T.; Cannon, R. O. 3rd; Alling, D.; et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N. Engl. J. Med. 1989, 321(16), 1061-8.
292. Frustaci, A.; Russo, M. A.; Chimenti, C. Randomized study on the efficacy of immunosuppressive therapy in patients with virusnegative inflammatory cardiomyopathy: the TIMIC study. Eur. Heart J. 2009, 30(16), 1995-2002.
293. Skudicky, D.; Sliwa, K.; Bergemann, A.; Candy, G.; Sareli, P. Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart 2000, 84(4), 438-9.
294. Sliwa, K.; Skudicky, D.; Candy, G.; Wisenbaugh, T.; Sareli, P. Randomised investigation of effects of pentoxifylline on leftventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998, 351(9109), 1091-3.
295. Sliwa, K.; Woodiwiss, A.; Candy, G.; Badenhorst, D.; Libhaber, C.; Norton, G.; Skudicky, D.; Sareli, P. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2002, 90(10), 1118-22.
296. Torre-Amione, G.; Sestier, F.; Radovancevic, B.; Young, J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J. Am. Coll. Cardiol. 2004, 44(6), 1181-6.
297. Keith, M. E.; Jeejeebhoy, K. N.; Langer, A.; Kurian, R.; Barr, A.; O'Kelly, B.; Sole, M. J. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am. J. Clin. Nutr. 2001, 73(2), 219-24.
298. Staudt, A.; Hummel, A.; Ruppert, J.; Dorr, M.; Trimpert, C.; Birkenmeier, K.; Krieg, T.; Staudt, Y.; Felix, S. B. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am. Heart J. 2006, 152(4), 712 e1-6.
299. Gullestad, L.; Aass, H.; Fjeld, J. G.; Wikeby, L.; Andreassen, A. K.; Ihlen, H.; Simonsen, S.; Kjekshus, J.; Nitter-Hauge, S.; Ueland, T.; Lien, E.; Froland, S. S.; Aukrust, P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001, 103(2), 220-5.
300. McNamara, D. M.; Holubkov, R.; Starling, R. C.; Dec, G. W.; Loh, E.; Torre-Amione, G.; Gass, A.; Janosko, K.; Tokarczyk, T.; Kessler, P.; Mann, D. L.; Feldman, A. M. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103(18), 2254-9.
301. Assmus, B.; Honold, J.; Schachinger, V.; Britten, M. B.; Fischer-Rasokat, U.; Lehmann, R.; Teupe, C.; Pistorius, K.; Martin, H.; Abolmaali, N. D.; Tonn, T.; Dimmeler, S.; Zeiher, A. M. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 2006, 355(12), 1222-32.
302. Pokushalov, E.; Romanov, A.; Chernyavsky, A.; Larionov, P.; Terekhov, I.; Artyomenko, S.; Poveshenko, O.; Kliver, E.; Shirokova, N.; Karaskov, A.; Dib, N. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study. J. Cardiovasc. Transl. Res. 2010, 3(2), 160-8.
303. Vrtovec, B.; Poglajen, G.; Lezaic, L.; Sever, M.; Domanovic, D.; Cernelc, P.; Socan, A.; Schrepfer, S.; Torre-Amione, G.; Haddad, F.; Wu, J. C. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ. Res. 2013, 112(1), 165-73.
304. Moertl, D.; Hammer, A.; Steiner, S.; Hutuleac, R.; Vonbank, K.; Berger, R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am. Heart J. 2011, 161(5), 915 e1-9.